Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa

Background: Neuroendocrine tumours are known to impact patients’ quality of life because of the symptoms caused by hypersecretion of serotonin and other peptides, in particular diarrhoea and flushing.Aim: The Q-SYMTU study was a prospective, observational registry that included 24 symptomatic patien...

Full description

Saved in:
Bibliographic Details
Published in:SA journal of oncology 2020-01, Vol.4 (1), p.1-7
Main Authors: Szpak, Waldemar M., Rodrigues, Sylvia, Nel, Monique, Harris, Jill, Pirjol, Anca I., Bouharati, Celia, Geldenhuys, Daleen, Rapoport, Bernardo L., McMaster, Alicia, Botha, Michiel, Fourie, Samuel, Jonas, Natalie
Format: Article
Language:English
Subjects:
Cancer therapies
Care and treatment
Diarrhea
Ethics
FDA approval
Gastroenteropancreatic neuroendocrine tumours
Lanreotide
Lanreotide Autogel
Neuroendocrine tumors
Neuroendocrine tumours
Oncology
Pancreas
Patient satisfaction
Peptides
Quality of life
Serotonin
Somatostatin analogues
Standard deviation
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Neuroendocrine tumours are known to impact patients’ quality of life because of the symptoms caused by hypersecretion of serotonin and other peptides, in particular diarrhoea and flushing.Aim: The Q-SYMTU study was a prospective, observational registry that included 24 symptomatic patients with gastroenteropancreatic neuroendocrine tumours.Setting: Multiple oncology practices in South Africa.Method: Patients’ level of satisfaction was evaluated for a 6-month period from initiation of treatment with lanreotide Autogel.Results: The number of patients who had greater than 50% self-reported reduction in daily episodes of diarrhoea and flushing were 67% and 80%, respectively, over a 6-month period.Conclusion: Treatment with lanreotide Autogel was generally well tolerated, as demonstrated by low occurrence of Grade 3 and Grade 4 adverse events (AEs). None of the Grade 4 AEs were related to the study treatment. No Grade 5 AEs were reported.
ISSN:2518-8704
2518-8704
DOI:10.4102/sajo.v4i0.138